Amicus Therapeutics, Inc. (FOLD)
NASDAQ
Market Cap
$2.87B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
584 of 809
Rank in Industry
320 of 445
Largest Insider Buys in Sector
FOLD Stock Price History Chart
FOLD Stock Performance
About Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Insider Activity of Amicus Therapeutics, Inc.
Over the last 12 months, insiders at Amicus Therapeutics, Inc. have bought $0 and sold $8.98M worth of Amicus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Amicus Therapeutics, Inc. have bought $272,878 and sold $13.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,500 shares for transaction amount of $15,735 was made by WHITMAN BURKE W (director) on 2021‑11‑01.
List of Insider Buy and Sell Transactions, Amicus Therapeutics, Inc.
| 2024-06-03 | Sale | Campbell Bradley L | President and CEO | 7,500 0.0025% | $10.00 | $75,000 | +0.30% | |
| 2024-05-01 | Sale | Campbell Bradley L | President and CEO | 7,500 0.0024% | $10.07 | $75,524 | -4.80% | |
| 2024-04-01 | Sale | Campbell Bradley L | President and CEO | 7,500 0.0025% | $11.67 | $87,496 | -13.45% | |
| 2024-03-05 | Sale | MCGLYNN MARGARET G | director | 7,500 0.0025% | $13.40 | $100,500 | -21.89% | |
| 2024-03-04 | Sale | MCGLYNN MARGARET G | director | 7,500 0.0025% | $13.29 | $99,675 | -22.55% | |
| 2024-03-01 | Sale | Campbell Bradley L | President and CEO | 15,833 0.0053% | $13.14 | $208,017 | -21.52% | |
| 2024-03-01 | Sale | Crowley John F | Executive Chairman | 29,181 0.01% | $13.35 | $389,543 | -21.52% | |
| 2024-02-15 | Sale | Campbell Bradley L | President and CEO | 4,167 0.0015% | $14.00 | $58,338 | -24.14% | |
| 2024-02-15 | Sale | Crowley John F | Executive Chairman | 31,614 0.0113% | $13.81 | $436,551 | -24.14% | |
| 2024-02-15 | Sale | Clark David Michael | Chief People Officer | 4,427 0.0016% | $14.00 | $61,978 | -24.14% | |
| 2024-02-07 | Sale | Rosenberg Ellen | Chief Legal Officer | 29,600 0.0104% | $13.00 | $384,818 | -18.00% | |
| 2024-02-06 | Sale | Rosenberg Ellen | Chief Legal Officer | 400 0.0001% | $13.00 | $5,200 | -17.80% | |
| 2024-02-01 | Sale | Campbell Bradley L | President and CEO | 15,833 0.0054% | $12.56 | $198,858 | -15.55% | |
| 2024-02-01 | Sale | Crowley John F | Executive Chairman | 31,614 0.0107% | $12.62 | $398,918 | -15.55% | |
| 2024-01-22 | Sale | Crowley John F | Executive Chairman | 55,327 0.0189% | $12.36 | $683,958 | -7.90% | |
| 2024-01-16 | Sale | Crowley John F | Executive Chairman | 31,614 0.0108% | $12.78 | $404,106 | -10.60% | |
| 2024-01-10 | Sale | Crowley John F | Executive Chairman | 31,614 0.0109% | $13.65 | $431,452 | -14.97% | |
| 2024-01-09 | Sale | Clark David Michael | Chief People Officer | 1,384 0.0005% | $14.00 | $19,376 | -16.17% | |
| 2024-01-09 | Sale | Prout Samantha | Chief Accounting Officer | 1,337 0.0005% | $14.00 | $18,718 | -16.17% | |
| 2024-01-08 | Sale | Clark David Michael | Chief People Officer | 8,726 0.003% | $14.00 | $122,164 | -18.23% |
Insider Historical Profitability
8.2%
| Campbell Bradley L | President and CEO | 886654 0.2985% | $9.70 | 3 | 72 | +51.18% |
| Crowley John F | Executive Chairman | 573478 0.256% | $9.70 | 5 | 162 | <0.0001% |
| Rosenberg Ellen | Chief Legal Officer | 367654 0.1254% | $9.70 | 1 | 12 | <0.0001% |
| Castelli Jeff | Chief Development Officer | 340661 0.1162% | $9.70 | 3 | 12 | |
| Clark David Michael | Chief People Officer | 253664 0.0909% | $9.70 | 0 | 8 | |
| Prout Samantha | Chief Accounting Officer | 80953 0.0276% | $9.70 | 0 | 11 | |
| MCGLYNN MARGARET G | director | 59289 0.0173% | $9.70 | 1 | 8 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 20724424 7.0672% | $9.70 | 19 | 1 | +38.1% |
| Redmile Group, LLC | 10 percent owner | 12956446 4.4183% | $9.70 | 1 | 0 | <0.0001% |
| PERRY MARK W | 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 1 | <0.0001% |
| BARRIS PETER J | 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 1 | <0.0001% |
| BARRETT M JAMES | director, 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 0 | <0.0001% |
| KRAMLICH C RICHARD | 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 1 | <0.0001% |
| NEWHALL CHARLES W III | 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 1 | <0.0001% |
| NEW ENTERPRISE ASSOCIATES 11 LP | 10 percent owner | 4584311 1.5633% | $9.70 | 1 | 1 | <0.0001% |
| FHM IV LP | 10 percent owner | 920664 0.314% | $9.70 | 32 | 0 | +2.58% |
| Topper James N | director | 920664 0.314% | $9.70 | 32 | 0 | +2.58% |
| Do Hung | Chief Science Officer | 409682 0.1397% | $9.70 | 0 | 18 | |
| Quimi Daphne | Chief Financial Officer | 398532 0.1359% | $9.70 | 3 | 21 | +74.63% |
| Barth Jay | Chief Medical Officer | 163204 0.0557% | $9.70 | 0 | 26 | |
| Weinhoff Gregory M | director | 129943 0.0443% | $9.70 | 0 | 1 | |
| Baird William D III | Chief Financial Officer | 117622 0.0401% | $9.70 | 3 | 13 | +74.63% |
| WHITMAN BURKE W | director | 65082 0.0222% | $9.70 | 19 | 0 | <0.0001% |
| Bloch Stephen M | director | 61700 0.021% | $9.70 | 0 | 89 | |
| RAAB MICHAEL | director | 60012 0.0205% | $9.70 | 0 | 7 | |
| Bleil Lynn Dorsey | director | 50310 0.0172% | $9.70 | 1 | 0 | +13.66% |
| BARER SOL J | director | 45000 0.0153% | $9.70 | 2 | 0 | <0.0001% |
| Patterson Matthew R | Acting CEO & President | 36449 0.0124% | $9.70 | 0 | 17 | |
| Andrews Kurt J. | SVP, Human Resources | 35469 0.0121% | $9.70 | 0 | 3 | |
| Palling David | Sr VP, Technical Operations | 34040 0.0116% | $9.70 | 0 | 16 | |
| BARKAS ALEXANDER E | director | 33608 0.0115% | $9.70 | 0 | 1 | |
| PROSPECT VENTURE PARTNERS II LP | 10 percent owner | 33608 0.0115% | $9.70 | 0 | 1 | |
| Dilone Enrique | SVP, Technical Operations | 30688 0.0105% | $9.70 | 3 | 6 | +51.18% |
| Valenzano Ken | SVP, Pharmacology & Biology | 27687 0.0094% | $9.70 | 3 | 9 | +51.18% |
| Schaeffer Orlov S Nicole | SVP, HR & Leadership Devt | 12582 0.0043% | $9.70 | 0 | 2 | |
| SBLENDORIO GLENN | director | 11933 0.0041% | $9.70 | 2 | 4 | +13.48% |
| HAYDEN DONALD J JR | director | 5814 0.002% | $9.70 | 0 | 2 | |
| Kirk John | VP, Regulatory Affairs | 5687 0.0019% | $9.70 | 0 | 2 | |
| Gershkowitz Jayne | SVP, Chief Patient Advocate | 5693 0.0019% | $9.70 | 3 | 6 | +43.43% |
| Peist Kenneth | VP, Legal & IP | 3187 0.0011% | $9.70 | 3 | 7 | +74.63% |
| Doshi Dipal | SVP Strategy & Bus Dev | 1706 0.0006% | $9.70 | 0 | 1 | |
| Winterbottom Joan | SVP, Human Resources | 1665 0.0006% | $9.70 | 1 | 0 | <0.0001% |
| Licholai Gregory P | VP, Medical Affairs | 152 0.0001% | $9.70 | 0 | 5 | |
| Yu Julie | VP Clinical Ops & Data Mgmt | 0 0% | $9.70 | 2 | 5 | |
| GLAXOSMITHKLINE PLC | 0 0% | $9.70 | 2 | 1 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| The Vanguard Group | $332.25M | 9.52 | 28.2M | -1.01% | -$3.39M | 0.01 | |
| Perceptive Advisors | $330.52M | 9.47 | 28.06M | 0% | +$0 | 0.21 | |
| Avoro Capital Advisors Llc | $322.77M | 9.25 | 27.4M | 0% | +$0 | 3.87 | |
| BlackRock | $269.17M | 7.71 | 22.85M | -0.6% | -$1.63M | 0.01 | |
| Wellington Management Company | $221.51M | 6.35 | 18.8M | +23.79% | +$42.57M | 0.04 | |
| JPMorgan Chase | $184.84M | 5.3 | 15.69M | -12.09% | -$25.41M | 0.02 | |
| Janus Henderson | $162.71M | 4.66 | 13.81M | +20.05% | +$27.18M | 0.09 | |
| Redmile Group | $156.17M | 4.48 | 13.26M | -10.6% | -$18.51M | 5.79 | |
| State Street | $146.57M | 4.2 | 12.44M | -5.47% | -$8.49M | 0.01 | |
| William Blair Investment Management | $135.78M | 3.89 | 11.53M | -1.04% | -$1.42M | 0.35 | |
| Morgan Stanley | $114.32M | 3.28 | 9.7M | -27.18% | -$42.68M | 0.01 | |
| Palo Alto Investors Lp | $110.07M | 3.16 | 9.34M | -9.93% | -$12.13M | 12.41 | |
| Macquarie Group | $83.29M | 2.39 | 7.07M | -2% | -$1.7M | 0.07 | |
| Geode Capital Management | $73.17M | 2.1 | 6.21M | +4.36% | +$3.06M | 0.01 | |
| Fiera Capital | $61.52M | 1.76 | 5.22M | +3.17% | +$1.89M | 0.18 | |
| American Century Investments | $56.55M | 1.62 | 4.8M | +4.78% | +$2.58M | 0.04 | |
| Deutsche Bank | $51.26M | 1.47 | 4.35M | -24.7% | -$16.82M | 0.02 | |
| Northern Trust | $37.18M | 1.07 | 3.16M | +10.94% | +$3.67M | 0.01 | |
| Massachusetts Financial Services Co Ma | $31.12M | 0.89 | 2.64M | +9.38% | +$2.67M | 0.01 | |
| Novo Holdings A/S | $29.45M | 0.84 | 2.5M | 0% | +$0 | 2.06 | |
| Bank of America | $29.24M | 0.84 | 2.48M | -8.35% | -$2.66M | <0.01 | |
| Blackstone | $29.06M | 0.83 | 2.47M | 0% | +$0 | 0.13 | |
| Charles Schwab | $27.41M | 0.79 | 2.33M | +2.56% | +$683,722.98 | 0.01 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $25.64M | 0.74 | 2.18M | +583.39% | +$21.89M | 0.09 | |
| Victory Capital Management Inc | $22.72M | 0.65 | 1.93M | +10.05% | +$2.08M | 0.02 | |
| Fidelity Investments | $20.59M | 0.59 | 1.75M | -20.37% | -$5.26M | <0.01 | |
| Standard Life | $19.11M | 0.55 | 1.62M | New | +$19.11M | 0.04 | |
| New York State Common Retirement Fund | $18.26M | 0.52 | 1.55M | +5.09% | +$884,727.35 | 0.02 | |
| Panagora | $18.01M | 0.52 | 1.53M | +9.44% | +$1.55M | 0.09 | |
| Great Point Partners | $17.62M | 0.51 | 1.5M | +16.79% | +$2.53M | 2.95 | |
| T. Rowe Price | $16.37M | 0.47 | 1.39M | +0.87% | +$141,406.81 | <0.01 | |
| Citadel Advisors LLC | $15.92M | 0.46 | 1.35M | +3,059.11% | +$15.41M | 0.01 | |
| Goldman Sachs | $15.81M | 0.45 | 1.34M | -36.78% | -$9.2M | <0.01 | |
| Voloridge Investment Management, LLC | $15.47M | 0.44 | 1.31M | +78.69% | +$6.81M | 0.04 | |
| BNY Mellon | $13.7M | 0.39 | 1.16M | -2.09% | -$292,520.94 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $13.58M | 0.39 | 1.15M | +8.35% | +$1.05M | 0.35 | |
| Nuveen | $13.52M | 0.39 | 1.15M | -18.18% | -$3M | <0.01 | |
| PRIMECAP Management Co | $12.89M | 0.37 | 1.09M | 0% | +$0 | 0.01 | |
| Voya Investment Management LLC | $12.17M | 0.35 | 1.03M | +6.43% | +$735,115.47 | 0.01 | |
| Rice Hall James & Associates, LLC | $12.12M | 0.35 | 1.03M | -3.51% | -$440,524.89 | 0.73 | |
| Artal Group S A | $11.92M | 0.34 | 1.01M | -50.07% | -$11.95M | 0.06 | |
| Renaissance Technologies | $11.26M | 0.32 | 956,200 | +1,135.4% | +$10.35M | 0.02 | |
| Granite Investment Partners Llc | $10.82M | 0.31 | 918,834 | New | +$10.82M | 0.41 | |
| Saturn V Capital Management Llc | $10.58M | 0.3 | 898,381 | +349.25% | +$8.23M | 4.24 | |
| UBS | $10.58M | 0.3 | 897,896 | +8.87% | +$862,154.65 | <0.01 | |
| Hudson Bay Capital Management LP | $9.45M | 0.27 | 802,500 | +122.92% | +$5.21M | 0.1 | |
| Candriam S C A | $9.42M | 0.27 | 799,823 | +44.4% | +$2.9M | 0.06 | |
| Invesco | $9.02M | 0.26 | 765,888 | +362.28% | +$7.07M | <0.01 | |
| Rafferty Asset Management Llc | $8.78M | 0.25 | 745,574 | -6.26% | -$586,373.08 | 0.03 | |
| PEREGRINE CAPITAL MANAGEMENT INC | $8.64M | 0.25 | 733,549 | +21.18% | +$1.51M | 0.25 |